Targeting fusion proteins of the interleukin family: A promising new strategy for the treatment of autoinflammatory diseases

This publication has 121 references indexed in Scilit:

• Side Effects of Cytokines Approved for Therapy
  Drug Safety, 2014
• Treating inflammation by blocking interleukin-1 in humans
  Seminars in Immunology, 2013
• Anti-interferon alpha treatment in SLE
  Clinical Immunology, 2013
• Effect of IL-17A blockade with secukinumab in autoimmune diseases
  Annals of the Rheumatic Diseases, 2013
• Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial
  Rheumatology, 2013
• IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage
  Osteoarthritis and Cartilage, 2012
• The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
  Nature Medicine, 2012
• A Th17-polarized cell population that has infiltrated the lung requires cells that convert to IFN-γ production in order to induce airway hyperresponsiveness
  International Immunology, 2010
• Interleukin 17 and RANTES levels in induced sputum of patients with allergic rhinitis after a single nasal allergen challenge
  Annals of Allergy, Asthma & Immunology, 2009
• A Fusion Protein Composed of IL‐2 and Caspase‐3 Ameliorates the Outcome of Experimental Inflammatory Colitis
  Annals of the New York Academy of Sciences, 2009